As a serum oncogenic biomarker of B-cell lymphoma, miR21 indicated B-lymphoma cell sensitivity to ABT-199 via ICOS/ICOSL-mediated interaction of Treg cells with endothelial cells. The gene discussed is ICOS; the disease is B-cell non-Hodgkin lymphoma.